摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-苯基乙炔基-呋喃-2-甲醛 | 1000402-17-4

中文名称
4-苯基乙炔基-呋喃-2-甲醛
中文别名
——
英文名称
4-(phenylethynyl)furan-2-carbaldehyde
英文别名
4-Phenylethynyl-furan-2-carbaldehyde;4-(2-phenylethynyl)furan-2-carbaldehyde
4-苯基乙炔基-呋喃-2-甲醛化学式
CAS
1000402-17-4
化学式
C13H8O2
mdl
——
分子量
196.205
InChiKey
TUFORXFWYVAOOP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    368.4±27.0 °C(Predicted)
  • 密度:
    1.21±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    15
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    30.2
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    4-苯基乙炔基-呋喃-2-甲醛 氢气乙酸乙酯 作用下, 以 甲醇 为溶剂, 反应 14.0h, 以to give 4-phenethyl-furan-2-carbaldehyde as a colorless oil (1.53 g, 97%)的产率得到4-phenethyl-furan-2-carbaldehyde
    参考文献:
    名称:
    FUSED HETEROCYCLES
    摘要:
    该发明提供了具有以下式的熔合杂环: 其中,R1是从H、取代或未取代的芳基烷基和取代或未取代的杂芳基烷基组成的群体中选择的一员。R2是从H、取代或未取代的烯基、取代或未取代的芳基烷基和取代或未取代的杂芳基烷基组成的群体中选择的一员。R3是从H、C1-C6取代或未取代的烷基、取代或未取代的芳基烷基和取代或未取代的杂芳基烷基组成的群体中选择的一员。R4是从OH和O-X+中选择的一员,其中X+是有机阳离子和无机阳离子中选择的一员。取代或未取代的芳基烷基和取代或未取代的杂芳基烷基基团具有以下式: 其中,Ar是从取代或未取代的芳基和取代或未取代的杂芳基组成的群体中选择的一员。指数n是从1到4的整数。
    公开号:
    US20100022612A1
  • 作为产物:
    描述:
    4-溴-2-呋喃甲醛苯乙炔 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide二异丙胺 作用下, 反应 2.0h, 以78%的产率得到4-苯基乙炔基-呋喃-2-甲醛
    参考文献:
    名称:
    通过钙(II)和铜(II)催化的反应序列一键组装高度官能化的环戊[b]吡咯
    摘要:
    描绘了一种用户友好的,钙(II)和铜(II)催化的一锅法反应序列,用于制备具有高度复杂性的环戊五烯[ b ]吡咯。该反应涉及以下顺序转化:(i)氮杂-Piancatelli环化,(ii)加氢胺化/异构化过程,(iii)随后的Friedel-Crafts型反应,从易于获得的2-呋喃基甲醇,苯胺中获得所需化合物和仲醇,需采取最少的预防措施。
    DOI:
    10.1002/adsc.201601301
点击查看最新优质反应信息

文献信息

  • Highly Regioselective Aromatic C–H Allylation of <i>N</i>-(Arylmethyl)sulfonimides with Allyl Grignard Reagents Involving Benzylic C–N Cleavage
    作者:Meng-Zeng Zhu、Dong Xie、Shi-Kai Tian
    DOI:10.1021/acs.orglett.1c02437
    日期:2021.9.3
    C–H functionalization of benzyl electrophiles with nucleophiles via palladium-catalyzed benzylic C–N cleavage. A range of N-(1-naphthylmethyl)sulfonimides, N-(2-thienylmethyl)sulfonimides, and N-(2-furanylmethyl)sulfonimides smoothly underwent palladium-catalyzed aromatic C–H allylation with allyl Grignard reagents at room temperature, delivering structurally diverse substituted 1-allylnaphthalenes and
    已经建立了一对新的反应伙伴,用于通过钯催化的苄基 C-N 裂解将苄基亲电试剂与亲核试剂的芳族 C-H 官能化。一系列N- (1-萘基甲基)磺酰亚胺、N- (2-噻吩基甲基)磺酰亚胺和N- (2-呋喃基甲基)磺酰亚胺在室温下与烯丙基格氏试剂顺利进行钯催化的芳族 C-H 烯丙基化,在结构上传递多种取代的 1-烯丙基萘和 2-烯丙基杂芳烃,产率中等至极好,具有极高的区域选择性。更换N-(芳甲基)磺酰亚胺与(芳甲基)铵盐、芳甲基氯化物或芳甲基磷酸酯作为苄基亲电试剂导致区域选择性的显着侵蚀。
  • FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE
    申请人:Heffernan L. R. Michele
    公开号:US20080004327A1
    公开(公告)日:2008-01-03
    This invention provides novel inhibitors of the enzyme D-amino acid oxidase as well as pharmaceutical compositions including the compounds of the invention. The invention also provides methods for the treatment and prevention of neurological disorders, such as neuropsychiatric and neurodegenerative diseases, as well as pain, ataxia and convulsion. The compounds of the invention have the general structure: wherein A is NH or S. Q is a member selected from CR 1 and N. X and Y are members independently selected from O, S, CR 2 , N and NH. R 1 , R 2 and R 4 are members independently selected from H and F, provided that at least one member selected from R 1 , R 2 and R 4 is F. R 6 is a member selected from O − X + and OH, wherein X + is a positive ion, which is a member selected from inorganic positive ions and organic positive ions.
    这项发明提供了D-氨基酸氧化酶的新型抑制剂,以及包括该发明中化合物的药物组合物。该发明还提供了用于治疗和预防神经系统疾病,如神经精神病和神经退行性疾病,以及疼痛、共济失调和抽搐的方法。该发明中的化合物具有一般结构:其中A为NH或S。Q是从CR1和N中选择的成员。X和Y分别是从O、S、CR2、N和NH中独立选择的成员。R1、R2和R4是从H和F中独立选择的成员,前提是至少选择R1、R2和R4中的一个成员为F。R6是从O−X+和OH中选择的成员,其中X+是正离子,从无机正离子和有机正离子中选择的成员。
  • Fused heterocyclic inhibitors of D-amino acid oxidase
    申请人:Heffernan L. R. Michele
    公开号:US20080058395A1
    公开(公告)日:2008-03-06
    This invention provides novel inhibitors of the enzyme D-amino acid oxidase as well as pharmaceutical compositions including the compounds of the invention. Also provided are methods for the treatment and prevention of neurological disorders, such as neuropsychiatric and neurodegenerative diseases, as well as pain, ataxia and convulsion. The compounds of the invention have the general structure: wherein Q is a member selected from O, S, CR 1 and N, X and Y are members independently selected from CR 2 , O, S, N and NR 3 .
    本发明提供了D-氨基酸氧化酶的新型抑制剂,以及包括该发明化合物的制药组合物。同时,还提供了治疗和预防神经系统疾病,如神经精神疾病和神经退行性疾病,以及疼痛、共济失调和惊厥的方法。该发明化合物具有以下一般结构:其中Q是从O、S、CR1和N中选择的成员,X和Y是独立选择自CR2、O、S、N和NR3的成员。
  • Fluoro-substituted inhibitors of D-amino acid oxidase
    申请人:Sepracor Inc.
    公开号:US07884124B2
    公开(公告)日:2011-02-08
    This invention provides novel inhibitors of the enzyme D-amino acid oxidase as well as pharmaceutical compositions including the compounds of the invention. The invention also provides methods for the treatment and prevention of neurological disorders, such as neuropsychiatric and neurodegenerative diseases, as well as pain, ataxia and convulsion. The compounds of the invention have the general structure: wherein A is NH or S. Q is a member selected from CR1 and N. X and Y are members independently selected from O, S, CR2, N and NH. R1, R2 and R4 are members independently selected from H and F, provided that at least one member selected from R1, R2 and R4 is F. R6 is a member selected from O−X+ and OH, wherein X+ is a positive ion, which is a member selected from inorganic positive ions and organic positive ions.
    本发明提供了D-氨基酸氧化酶的新型抑制剂,以及包括本发明化合物的制药组合物。本发明还提供了用于治疗和预防神经系统疾病,如神经精神疾病和神经退行性疾病,以及疼痛、共济失调和抽搐的方法。本发明化合物具有以下一般结构: 其中A为NH或S。Q为选择自CR1和N的成员。X和Y是独立选择自O、S、CR2、N和NH的成员。R1、R2和R4是独立选择自H和F的成员,但至少选择自R1、R2和R4中的一个成员为F。R6为选择自O−X+和OH的成员,其中X+为正离子,其为选择自无机正离子和有机正离子的成员。
  • Fused heterocycles
    申请人:Sepracor Inc.
    公开号:US07579370B2
    公开(公告)日:2009-08-25
    This invention provides fused heterocycles having the formula: in which R1 is a member selected from the group consisting of H, substituted or unsubstituted arylalkyl and substituted or unsubstituted heteroarylalkyl. R2 is a member selected from the group consisting of H substituted or unsubstituted alkenyl, substituted or unsubstituted arylalkyl and substituted or unsubstituted heteroarylalkyl. R3is a member selected from the group consisting of H, C1-C6 substituted or unsubstituted alkyl, substituted or unsubstituted arylalkyl and substituted or unsubstituted heteroarylalkyl. R4 is a member selected from OH and O−X+, in which X+ is positive ion which is a member selected from organic positive ions and inorganic positive ions. Substituted or unsubstituted arylalkyl and substituted or unsubstituted heteroarylalkyl moieties have the formula: in which Ar is a member selected from the group consisting of substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl. The index n is an integer from 1 to 4.
    该发明提供了具有以下式的融合杂环:其中R1是从H、取代或未取代的芳基烷基和取代或未取代的杂芳基烷基组成的群体中选择的成员。R2是从H、取代或未取代的烯基、取代或未取代的芳基烷基和取代或未取代的杂芳基烷基组成的群体中选择的成员。R3是从H、C1-C6取代或未取代的烷基、取代或未取代的芳基烷基和取代或未取代的杂芳基烷基组成的群体中选择的成员。R4是从OH和O−X+中选择的成员,其中X+是有机阳离子和无机阳离子中选择的成员之一的正离子。取代或未取代的芳基烷基和取代或未取代的杂芳基烷基基团的式为:其中Ar是从取代或未取代的芳基和取代或未取代的杂芳基组成的群体中选择的成员。指数n是1至4之间的整数。
查看更多